Jay Campbell is the Co-Founder and Chief Strategy Officer of BioLongevity Labs, a company developing advanced wellness formulations and bioregulator compounds that support human performance and research innovation. He has spent more than two decades studying how disciplined science, lifestyle, and mindset intersect to improve quality of life.
Let’s make it clear. He’s pro-peptide but as you’ll read below, very open to all sides, especially when it comes to doing what’s best for you.
I first came across Jay’s work while going down a rabbit hole on recovery science after breaking my ankle. Lots of athletes said, “Have you thought about peptides?” What struck me about Jay wasn’t the depth of his knowledge, though that’s obvious, it was his refusal to oversell like Huberman or Peter Attia do. In a space full of hype, he’s straightforward. I wanted to sit down with him and ask the questions I knew our audience had but can’t get straight answers on.
Scott: Jay, thanks for making time. Let’s just get right into it. In your experience working with athletes, what’s the number one misconception they have when they first come to you asking about peptides?
The biggest one is that a peptide is a shortcut. Athletes are conditioned to look for the edge, the thing that gets them there faster, and they walk in assuming a peptide will let them skip the foundational work.
It won’t.
Peptides are signaling molecules. They work with your existing biology to amplify or restore functions, not override the basics.
If your sleep is garbage, your protein intake is inconsistent, and your training is unstructured, no compound is going to save you.
The peptide is the precision tool you reach for after the fundamentals are dialed in, not instead of them.
Elite athletes understand this, and already have the discipline part down. Those are the ones who get the most benefit from peptides.
Scott: That framing of peptides as a precision tool, not a shortcut should reframe how a lot of people think about this. But before we go deeper, I want to clear up something that still causes confusion out there. How do you explain to an athlete the difference between a peptide and a steroid?
It’s a fair confusion, and the short answer is they operate on completely different principles.
Anabolic steroids are synthetic hormones that flood your system and force a response, often overriding your body’s natural feedback loops.
Peptides are short chains of amino acids that act as messengers. They bind to specific receptors and trigger a targeted biological response, and many of the therapeutic ones are bioidentical or near-bioidentical to compounds your body already produces.
So the mental model I give athletes is this: a steroid is a sledgehammer, and a peptide is a key. One forces the door; the other fits the lock. That specificity is the whole point.
A growth hormone secretagogue like Ipamorelin doesn’t dump synthetic hormone into you. It prompts your own pituitary to release growth hormone in a more natural, pulsatile way. That’s a fundamentally different paradigm than what people picture when they hear “steroid.”
I want to be clear, though: different mechanisms don’t mean no rules. We’ll get to the compliance side, because for a competitive athlete that’s where this gets serious.
Scott: “The sledgehammer versus the key.” I love that. Let’s get practical. When we’re talking about delivery methods, is there a meaningful difference in outcomes between subcutaneous injection and oral delivery for musculoskeletal injuries — or is the injection route always going to win?
For peptides specifically, the route of administration matters enormously, and it comes down to bioavailability.
Peptides are chains of amino acids, and that structure makes them highly susceptible to enzymatic breakdown. When you swallow one, it has to survive stomach acid, liver metabolism, and intestinal enzymes before anything reaches your bloodstream. A huge percentage of the active compound is degraded before it ever gets to work.
Subcutaneous injection bypasses all of that and is the highest impact delivery system. You’re delivering the compound systemically, at a known dose, with far more predictable and measurable results.
For musculoskeletal repair, where you want a reliable concentration of the compound actually circulating and reaching the tissue, injection is going to win in the vast majority of cases.
Of course, there is also a meaningful difference between subcutaneous and intramuscular injections, where different peptides call for different injection routes based on variables like absorption, location, and dosage volume.
Oral formats exist and the delivery science is improving, but as of today, for most therapeutic peptides, the injectable route delivers efficacy the oral route just can’t match.
Scott: Our audience is almost entirely endurance athletes, active runners, cyclists, triathletes. A lot of them are dealing with exactly the kind of chronic tissue stress you’re describing. Is there a scenario where a peptide protocol genuinely makes sense for that athlete, and what does that look like under proper medical supervision?
Yes, and the most defensible scenario is recovery and tissue repair, not performance enhancement.
Endurance athletes accumulate an enormous repetitive-load burden: tendons, ligaments, connective tissue under chronic stress. That’s exactly the kind of repair context where compounds like BPC-157 and TB-500 have generated real interest, with a substantial mechanistic and animal-research base behind them.
But the supervision piece is non-negotiable.
An effective protocol starts with comprehensive bloodwork, a clearly defined goal tied to a specific recovery need, and ONE compound at a time so you can attribute cause and effect. I advise dosing conservatively and titrating up slowly, as necessary, while cycling the peptide responsibly to preserve receptor sensitivity.
Work with a practitioner who actually understands this space and can monitor your biomarkers throughout.
Critically for any competitive endurance athlete, make sure to include a compliance check against your governing body before anything goes in your body. I’ve been doing this for over two decades, and I can tell you the athletes who get the best outcomes are the ones who treat the process like a science, not a shortcut.
Scott: You mentioned compliance, and I want to come back to that. But first — our audience is resourceful, and a lot of them have already been doing their own research. What does a red flag look like when an athlete shows you a protocol they found online, and what are the dumbest myths you keep seeing in this space?
The first red flag is the stack.
When someone shows me five or six compounds running simultaneously, I know immediately they read about all of them, got excited, and threw everything in at once. Now they have no idea what’s working, what’s causing any side effect, and they’ve made it impossible to learn anything useful about their own body.
Start with one goal and one compound. Master that before you add complexity.
Another red flag is the absence of any sourcing information. If they can’t tell me where the compound came from or whether it was independently verified for purity and identity, that’s the whole game right there. The quality problem in this space is real, and a mislabeled or contaminated compound can actively harm you while also making it impossible to know whether the peptide itself even works.
I look for independent, third-party certificates of analysis from accredited labs: genuinely independent verification, not an in-house claim. For most research-grade peptides you want purity above 98%, plus batch and lot traceability.
As for the dumbest myths: the biggest is “more is better.” With peptides, more is frequently worse. You get receptor desensitization and side effects that are entirely avoidable if you just start low and go slow.
A close second is the idea that because something is “natural” or bioidentical, it carries no risk and needs no plan. Everything you put in your body carries risk. The right question is never “is there risk?” — it’s whether the risk-benefit profile is favorable for you, with a real plan around it.
Scott: Okay, the compliance question — this is a big one for our audience because a lot of them are competitive athletes racing under USADA or WADA rules. How do you counsel those athletes about peptides, especially when they’re coming to you in the middle of an injury and desperate to get back?
Bluntly and without exception.
If you compete under WADA or USADA, you check the Prohibited List before you even think about putting anything in your body. When in doubt, don’t do it.
Now, do I think the current prohibited substance framework makes sense? No. A lot of it is outdated, politically driven, or completely disconnected from the actual science. The idea that helping your body recover from injury more efficiently is somehow “cheating” has always struck me as absurd. These governing bodies are often well behind the research, and athletes pay the price for that ignorance.
But the rules are the rules, and if you compete under those rules, you live with them. Period.
A doping violation could cost you more than a minor injury, and no compound is worth ending your career. Many of the peptides we’re discussing — growth hormone secretagogues, several of the repair compounds athletes are most curious about — are prohibited in competition, and in many cases prohibited at ALL times. That’s not a gray area.
So if you’re a competitive athlete sitting in front of me, I’m going to be straight with you. There is a wide world of recovery strategy that’s fully compliant, and that’s where you need to put your energy. Save the advanced protocols for when your competitive career is behind you, or until the governing bodies finally catch up to the science.
I wouldn’t hold my breath on that second one.
Scott: That’s as straight as it gets. Let’s talk injury recovery specifically, because this is where I think a lot of endurance athletes are most curious. When someone is hurt and wants to get back faster, are peptides actually going to help — or is it just patience and RICE?
It’s not either/or, and anyone who tells you a peptide replaces the fundamentals is selling you something.
Foundational work — rest, load management, progressive rehab, sleep, protein, and basic RICE principles in the acute phase — is what drives healing. That’s 80% of the equation. You can’t substitute a compound for it.
Within that framework, certain peptides have a genuinely interesting role as accelerants for tissue repair. The compound I get asked about most for injury recovery is what is often called the Wolverine Stack, a blend of BPC-157 and TB-500. The evidence behind these compounds for connective tissue repair, wound healing, and reducing inflammation is substantial, and I’ve documented their effects on my own recovery for years.
When the fundamentals are dialed in and you layer this stack on top, the recovery acceleration is unlike anything else I’ve seen in over two decades of self-experimentation.
Now, for competitive athletes, I have to be clear. This stack IS on the WADA Prohibited List. So if you compete under those rules, this is not an option for you right now, regardless of how effective it is.
But notice the framing regardless of who you are. It’s an accelerant, not a replacement. If you skip the rehab and just inject something, you’ll get a worse outcome. You’ll mask a problem instead of resolving it, or you’ll return to load before the tissue is ready.
Used intelligently, on top of disciplined rehab and under proper supervision, peptides can help you recover faster and more completely. Used as a substitute for patience and proper rehabilitation, they’re a mistake.
Scott: The Wolverine Stack — I hadn’t heard that term before this conversation, and I guarantee half our readers are googling it right now. Let’s zoom out to the regulatory picture. With the FDA reclassification happening in 2026, do you think we’ll start seeing more rigorous human trial data, or is the research still going to lag behind the market?
Both, honestly.
The regulatory direction is genuinely shifting, and that matters. Clearer regulatory pathways tend to unlock the kind of formal research investment that’s been absent. So I’m optimistic that we’ll see more rigorous human data over the coming years.
But I’d set realistic expectations: rigorous human trials are slow and expensive by design, and there’s a structural economics problem underneath all of this. You can’t easily patent a naturally occurring amino acid sequence, which means there’s been limited commercial incentive to fund large human trials for many of these compounds. That’s a big part of why the human data has lagged — it’s an economics and incentives story as much as a science story.
So even with a more favorable regulatory environment, I expect the market and real-world use to keep running ahead of the published trial literature for some time. That gap is precisely why sourcing discipline, conservative protocols, biomarker tracking, and working with a knowledgeable practitioner matter so much right now.
We’re operating at the frontier, and the responsible posture is to acknowledge that honestly rather than pretend a 30-year safety database exists where it doesn’t.
Scott: Last one, and I want to make it count. If you could tell every endurance athlete one thing about peptides that they’re almost certainly getting wrong, what would it be?
That the compound is the smallest variable in the equation.
Many endurance athletes obsess over the exotic, marginal-gain stuff while leaving enormous performance and recovery gains on the table in sleep, protein intake, and structured recovery. If you’re not sleeping well, eating enough protein to support tissue repair, and managing your training load intelligently, a peptide isn’t going to fix that. It can’t.
Get the foundation right first.
Then, if you’ve done that and you’re operating within the rules of your sport and under real medical supervision, precision tools like peptides can help you go further.
The athletes who understand that order of operations are the ones who actually benefit. The ones who get it backwards just spend money chasing an edge they were never positioned to use in the first place.
You can follow Jay Campbell’s work and research at jaycampbell.com.
Leave a Reply
You must be logged in to post a comment.